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A B S T R A C T
Background: The prognosis of diabetic kidney disease is poor because epidemiological data have shown
that all-cause mortality increases with declining renal function. This study aims to estimate the annual
mortality rate of diabetic kidney disease stratiﬁed by chronic kidney disease (CKD) stages and to iden-
tify the predictors of mortality.
Methods: Patients with Stage 3–5 CKD (estimated glomerular ﬁltration rate [eGFR] less than 60 mL/
min per 1.73 m2) with diabetic kidney disease from the National Healthcare Group CKD Registry from 1
January 2007 to 31 December 2007 were included in this study. The patients were followed up till 30
November 2013. Cox’s proportional hazards regression modelling was used to assess the factors asso-
ciated with all-cause mortality.
Results: Over a median follow up period of 6.0 years, 985 out of 3008 patients (32.8%) died. Of those
who died, 363 (36.9%) died from cardiovascular causes. The annual mortality rate was 64.1 per 1000 in-
dividuals (95% conﬁdence interval [CI] 60.2–68.3) and the mortality rate increased with severity of CKD
[Stage 3A (37.0), Stage 3B (57.5), Stage 4 (98.3) and Stage 5 (198.5)]. Predictors of mortality were age,
male gender, CKD stages, albuminuria, comorbid conditions such as peripheral vascular disease, neu-
ropathy, retinopathy and the use of antiplatelet agents.
Conclusion: Our study estimated the annual all-cause mortality rate for Singaporean patients with di-
abetic kidney disease by CKD stages and identiﬁed predictors of all-cause mortality. This study has aﬃrmed
the poor prognosis of these patients and an urgency to intervene early so as to retard the progression to
later stages of CKD.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
Chronic kidney disease (CKD) is deﬁned as either functional or
structural kidney damage or an estimated glomerular ﬁltration rate
(eGFR) <60 mL/min per 1.73 m2 for at least 3 months [1]. CKD has
5 stages (stage 1 to stage 5) with stage 3 being subdivided into stages
3A and 3B based on the eGFR.
Worldwide, theprevalenceof CKD isestimated tobe7.2% inpersons
aged 30 years and above, with the prevalence varying from 23.4% to
35.8% in persons aged 64 years and above [2]. According to the 2010
Global Burden of Disease study CKD was ranked 18th in the list of
causes of global deaths (annual death rate of 15.7 per 100,000) [3].
The prognosis of patients with CKD is poor [4] because lower
eGFR and albuminuria are associated with incident cardiovascular
disease and all-cause mortality [5,6]. A systematic review showed
that the unadjusted relative risk for all-cause mortality in CKD pa-
tients compared with non-CKD patients ranged from 0.94 to 5.0 and
was signiﬁcantly higher (relative risk more than 1.0) in 93% of the
cohorts included [7]. The corresponding unadjusted relative risk for
cardiovascular mortality ranged from 1.4 to 3.7 [7]. In Singapore, a
recent study showed that the risks of both cardiovascular deaths
and all-cause mortality increase with decreasing estimated GFR and
increasing albuminuria [5]. The association between estimated GFR
<60 mL/min per 1.73 m2 and all-cause mortality was even stron-
ger among those with diabetes [5]. Furthermore, Singapore has the
ﬁfth highest incidence of end-stage renal failure in the world and
the highest incidence of diabetic nephropathy causing end-stage
renal failure compared to other countries [8]. A recent study has
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also found that the prevalence of diabetic nephropathy in a primary
health cluster in Singapore is as high as 52.5% [9].
Therefore, it is important to be cognizant of the mortality rate
in patients with chronic kidney disease for the purpose of health
service provision planning. This study aims to quantify the mor-
tality rate among diabetic CKD patients and to determine the
predictors associated with all-cause mortality for these patients.
The stage stratiﬁed mortality rates will provide a good estimate of
the population heathwhile the predictors of mortality will help prog-
nosticate patients for early and appropriate interventions to mitigate
their risks of renal failure progression thereby reducing subse-
quent morbidity and mortality.
Methods
The National Healthcare Group (NHG) provides public health-
care services through an integrated network of primary healthcare
polyclinics, acute care and tertiary hospitals, national specialty
centres and business divisions [10]. Patients in the NHG CKD Reg-
istry were identiﬁed to have CKD if they were at least 16 years old
and fulﬁlled any one of the following conditions:
1. Coded with CKD diagnosis [International classiﬁcation of disease
codes, ninth edition (585, 585.1, 585.2, 585,3, 585.4, 585.5, 585.6,
585.9)];
2. Two eGFR <60 mL/min/1.73 m2 90 days apart;
3. Two urine albumin creatinine ratio (ACR) ≥2.5 mg/mmol (male)
for males or ≥3.5 mg/mmol for females, or >30 mg/g taken 90
days apart
4. Two urine protein creatinine ratio (PCR) ≥20mg/mmol or >0.2mg/
mg 90 days apart;
5. Two urine protein ≥0.2 g/day 90 days apart.
All patients who fulﬁlled the above criteria will be automati-
cally included in the CKD registry. In addition, the CKD Registry
contains administrative, clinical and pharmacy information of these
patients, which would be extracted for the purpose of this study.
This is a retrospective cohort study of Type 2 diabetes patients
with CKD stage 3A and above (estimated glomerular ﬁltration rate
<60 mL/min per 1.73 m2) from the Registry from 1 January 2007 to
31 December 2007. Patients with CKD stages 1–2 or unknown CKD
stage status were excluded from the study.
To ensure comprehensive capture of all diabetes patients into
the registry, the following rules, ranked in descending order, were
used:
(i) Rule 1, patients from existing standalone diabetes registries;
(ii) Rule 2, patients with diagnosis code of §250 (§250.0–§250.9)
under the International Classiﬁcation of Diseases, 9th Revi-
sion, Clinical Modiﬁcation (ICD9CM), coded as either the
primary or secondary diagnosis;
(iii) Rule 3, patients on anti-diabetes medication; and
(iv) Rule 4, patients with 2-hour blood sugar level of ≥11.1mmol/L
on oral glucose tolerance test (OGTT), or a random blood sugar
level of ≥11.1mmol/L on 2 occasions within 2 years, or fasting
plasma glucose ≥7.0 on 2 occasions within 2 years, or random
blood sugar level of ≥11.1 mmol/L and fasting plasma glucose
≥7.0 within 2 years [11].
Variables extracted from the CKD Registry for the study in-
cluded demographic data (age, gender and ethnicity), diabetes onset
age, duration of diabetes, comorbidities (hypertension, dyslipidaemia,
ischaemic heart disease, cerebrovascular disease, retinopathy, pe-
ripheral vascular disease and neuropathy), use of medications
[angiotensin converting enzyme inhibitor (ACEi) and/or angioten-
sin receptor blocker (ARB), statins, oral hypoglycaemic agents and/
or insulin and antiplatelet agents] and laboratory results (glycated
haemoglobulin [HBA1c], serum creatinine, eGFR and albumin-
uria). Serum creatinine wasmeasured using an Isotope DilutionMass
Spectrometry (IDMS) traceable standard and eGFR was estimated
using the abbreviated Modiﬁcation of Diet in Renal Disease (MDRD)
equation. Microalbuminuria was deﬁned as urine ACR 2.5–30 mg/
mmol for males, urine ACR 3.5–30 mg/mmol for females, or urine
PCR 20–50 mg/mmol or total urinary protein 0.2–0.5 g/day.
Macroalbuminuria was deﬁned as urine ACR >30mg/mmol or urine
PCR >50 mg/mmol or total urinary protein >0.5 g/day.
Mortality data were obtained from the relevant local death reg-
istry. Patients were followed up until 30 November 2013 where the
outcomes of interest were deaths from all causes. In Singapore, the
law requires all deaths occurring in Singapore to be registered within
24 hours of occurrence and a certiﬁcate of cause of death issued
by doctors or authorized medical practitioners is required. Deaths
were considered to be from cardiovascular causes if they were due
to ischaemic heart diseases (ICD10: I20–I25), cerebrovascular dis-
eases (ICD 10:I60–69), hypertensive diseases (ICD10: I10–I15) and
other heart diseases (ICD10:I00–I09, I26–I51).
Statistical analysis
Characteristics of the study population are described for cate-
gorical variables by n (%) and for continuous variable as the
mean ± SD. The unadjusted overall time to deathwas described using
the Kaplan–Meier survival curve. Five year survival estimates (by
CKD stage) were obtained via life tables. Univariate Cox’s propor-
tional hazards regression was used to assess associations, measured
as hazard ratios (HR), between variables and all-cause deaths, fol-
lowed by multivariate Cox’s proportional hazards regression. The
level of signiﬁcance was set at p ≤ 0.20 for consideration to be used
in multivariate regression using backward elimination of non-
signiﬁcant variables with p = 0.05 for the ﬁnal model. All analyses
were conducted using STATA (StataCorp, College Station, TX, USA)
statistical software, version 12.0. The study was approved by the
NHG’s Domain-speciﬁc Ethics Review Board which is an indepen-
dent committee constituting of medical, scientiﬁc and non-scientiﬁc
members.
Results
Description
There were a total of 3008 Type 2 diabetes patients in 2007 who
met the study criteria, i.e. stages 3A and above, and were followed
up until 30 November 2013 (Table 1). A total of 19 patients were
excluded from the survival analysis as they died at the start of the
study. The mean age of the study cohort was 70.0 (standard devi-
ation: 10.4) years. Majority (72.5%) of patients belonged to CKD stages
3A and 3B and had hypertension (95.8%) and dyslipidaemia (97.6%).
At least 84.6% of patients were on ACEi, ARB or both.
Mortality rate
The median follow-up period was 6.0 years (range 0– 6.9 years).
During the study period, 985 (32.8%) participants died, of whom
majority (363, 36.9%) died from cardiovascular causes (Table 2). The
annual all-cause mortality rate over the study period was 64.1 per
1000 individuals (95% CI 60.2–68.3) per year and that of cardio-
vascular mortality was 23.8 per 1000 individuals (95% CI 21.5–
26.4) per year (Fig. 1). There was a progressive increase in annual
mortality rate with advancing CKD stages from 37.0 per 1000 in-
dividuals (95% CI 32.5–42.3) among patients with stage 3A to 57.5
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per 1000 individuals (95% CI 51.6–64.2) among those with stage 3B;
98.3 per 1000 individuals (95%CI 87.3–110.6) among thosewith stage
4; and 198.5 per 1000 individuals (95% CI 169.2–233.0) among those
with stage 5. There was also a progressive increase in annual mor-
tality rate with increasing amount of albuminuria at baseline from
31.3 per 1000 individuals (95% CI 24.5–39.9) among patients with
no albuminuria to 45.7 per 1000 individuals (95% CI 40.5–51.6)
among those with microalbuminuria and 80.8 per 1000 individu-
als (95%CI 73.3–89.1) among those with macroalbuminuria.
The overall median time to death was 2.9 years (range 0–6.2
years). Those with CKD stage 3A had a median 3.3 years to death,
longer compared with those in stage 3B (3 years), stage 4 (2.9 years)
and stage 5 (1.8 years). Those without albuminuria had a median
3.5 years to death, followed by those with microalbuminuria (2.9
years) and macroalbuminuria (3.2 years).
Overall survival
The ﬁve year overall survival estimate for all patients was 72.9%
(95% CI 71.3%–74.4%) There was a progressive decrease in ﬁve year
overall survival with advancing CKD stages from 83.9% (95% CI 81.6%–
85.9%) among patients with stage 3A to 75.1% (95% CI 72.4%–
77.6%) among those with stage 3B; 62.2% (95% CI 58.2%–65.9%)
among those with stage 4; and 37.6% (95% CI 31.3%–43.9%) among
those with stage 5. There was also a progressive decrease in ﬁve
year overall survival with increasing amount of albuminuria at base-
line from 86.4% (95% CI 82.5%–89.5%) among patients with no
albuminuria to 80.1% (95% CI 77.6%–82.3%) among those with
microalbuminuria and 66.7% (95%CI 63.8%–69.5%) among those with
macroalbuminuria.
Predictors of mortality
Univariate Cox’s proportional hazards regression analysis for the
study population showed signiﬁcantly higher hazard ratios with in-
creasing age and diabetes onset age, increasing creatinine level,
albuminuria severity, advancing CKD stages, comorbid conditions,
male gender and the use of drugs such as insulin and antiplatelet
agents. There was an inverse association of mortality (signiﬁ-
cantly lower hazard ratios) with eGFR and the use of drugs such
as ACEi and/or ARB, oral hypoglycaemic agents and statins (Table 3).
Multivariate Cox’s proportional hazards regression showed signif-
icant independent associations between death with increasing age,
male gender, advancing CKD stage, albuminuria severity, comorbid
conditions such as peripheral vascular disease, neuropathy and reti-
nopathy and the use of antiplatelet agent (Table 4).
Discussion
This study estimated the annual all-cause mortality rate of pa-
tients with diabetic kidney disease to be 64.1 per 1000 individuals
and this rate can be used for future healthcare service provision plan-
ning. We have also provided the annual all-cause mortality rate by
stages of CKD and albuminuria level and this would also help doctors
in communicating the prognosis to their patients, and emphasize
Table 1
Baseline characteristics of the study population
n = 3008
Age in years, mean (SD) 70.0 (10.4)
Diabetes onset age in years, mean (SD) 63.3 (12.4)
Gender
Male, no. (%) 1533 (50.3)
Ethnic group
Chinese, no. (%) 2115 (70.3)
Malay, no. (%) 556 (18.5)
Indian, no. (%) 222 (7.4)
Others and unknown, no. (%) 115 (3.8)
Duration of diabetes in years, mean (SD) 6.7 (6.7)
HBA1c in %, mean (SD) 7.7 (1.6)
Creatinine, mean (SD) 170.2 (119.5)
Glomerular ﬁltration rate in mL/min per 1.73 m2, mean (SD) 38.2 (14.0)
CKD stage
3A, no. (%) 1091 (36.3)
3B, no. (%) 1088 (36.2)
4, no. (%) 603 (20.1)
5, no. (%) 226 (7.5)
Albuminuria
None, no. (%) 375 (12.5)
Microalbuminuria, no. (%) 1094 (36.4)
Macroalbuminuria, no. (%) 1025 (34.1)
Unknown, no. (%) 514 (17.1)
Comorbid conditions
Dyslipidaemia, no. (%) 2935 (97.6)
Hypertension, no. (%) 2883 (95.8)
Ischaemic heart disease, no. (%) 684 (22.7)
Cerebrovascular disease, no. (%) 352 (11.7)
Retinopathy, no. (%) 350 (11.6)
Peripheral vascular disease, no. (%) 180 (6.0)
Neuropathy, no. (%) 127 (4.2)
Medications
ACEi/ARB
None, no. (%) 463 (15.4)
ACEi, no. (%) 1558 (51.8)
ARB, no. (%) 632 (21.0)
Both, no. (%) 355 (11.8)
Diabetes treatment
Diet, no. (%) 468 (15.6)
Oral hypoglycaemic agents only, no. (%) 1762 (58.6)
Insulin only, no. (%) 219 (7.3)
Both oral hypoglycaemic agents and insulin, no. (%) 559 (18.6)
Statin, no. (%) 2429 (80.8)
Antiplatelet agent, no. (%) 1235 (41.1)
Follow up period in years
Mean (SD) 5.0 (1.8)
Median (Range) 6.0 (0–6.9)
Table 2
Causes of death
Causes of death n = 985 (%)
Cardiovascular 363 (36.9)
Ischaemic heart diseases 250
Cerebrovascular diseases 69
Hypertensive heart diseases 15
Other heart diseases 29
Respiratory 189 (19.2)
Inﬂuenza and pneumonia 147
Malignant neoplasm of trachea, bronchus and lung 33
Other respiratory diseases 9
Renal 120 (12.2)
Nephritis, nephrotic syndrome and nephrosis 107
Unspeciﬁed disorder of kidney and ureter 8
Malignant neoplasm of kidney and renal pelvis 5
Gastrointestinal 82 (8.3)
Malignant neoplasm of liver and intraheptic ducts 28
Malignant neoplasm of colon, rectum and anus 14
Malignant neoplasm of pancreas 8
Malignant neoplasm of stomach 8
Chronic liver disease and cirrhosis 6
Peptic ulcer 4
Others 14
Endocrine 88 (8.9)
Diabetes mellitus 88
Urological 66 (6.7)
Other disorders of urethra and urinary tract 42
Urinary tract infection, site not speciﬁed 13
Malignant neoplasm of bladder 6
Malignant neoplasm of prostate 5
Others and unknown 77 (7.8)
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to them the importance of preventing progression to later stages
of CKD.
Among those who died, more than one third died of cardiovas-
cular causes and this is consistent with other studies that had
conﬁrmed chronic kidney disease as being an independent risk
factor for the development of cardiovascular disease (CVD) and
subsequent deaths from cardiac causes [5,12,13]. Thus, for these
patients, it is even more important to optimize the control of
their cardiovascular risk [14] and to regard them as the “highest
risk” group for CVD, irrespective of the levels of traditional CVD
risk factors [1].
The management of early stages of CKD is currently done in the
primary care setting. In Singapore, primary healthcare is provided
through a network of 18 outpatient polyclinics (public sector) and
1500 private medical practitioners clinics. Obstacles exist in the
private sector such as the lack of patient trust, experience and com-
munication with the specialist and the inability of the patient to
afford a higher healthcare cost [15]. As for the public sector, it ac-
counts for 45% of the chronic attendances while deploying only 14%
of all resident general practitioners in Singapore [16] even though
it was designed to meet 20% of the total demand for primary health-
care. This problem has been looked into by policymakers and changes
have been made to lower the age cut-off for lower income pa-
tients to qualify for portable subsidies to be used in the private
primary care sector [16].
Majority of patients in the study were already on ACEi and/or
ARB but our study did not show the beneﬁt of the use of ACEi and/
or ARB in reducing all-cause mortality after adjustments. Our results
differ from a recent large cohort study that showed that ACEi/ARB
administration was associated with greater survival [17]. The study
conducted by Molnar et al. reported that 30% of the original cohort
(which included non-diabetes patients) had not been exposed to
ACEi/ARBs [17] but our study comprised of only 15.4% that were
naïve to ACEi/ARBs. This may explain why the association of ACEi
and/or ARBs in our study became non-signiﬁcant after adjustment.
We have also found that the mortality rate is higher with in-
creasing albuminuria level and increasing CKD stages which are
consistent with the new classiﬁcation of CKD which classify CKD
by cause, GFR category and albuminuria category [14]. These ﬁnd-
ings are similar to others studies in other populations [6,18].
However, the use of this new classiﬁcation has yet to be incorpo-
rated into the guidelines in primary care in Singapore and it may
be timely to update it.
The use of antiplatelet agent was found to be associated with
higher mortality but the use of aspirin is recommended for sec-
ondary prevention of cardiovascular events [14]. It is interesting to
note that low dose aspirin therapy did not reduce atherosclerotic
events of fatal and nonfatal ischaemic heart disease, stroke, and pe-
ripheral arterial disease in patients with eGFR <90 ml/min/1.73 m2
in a subanalysis from the JPAD trial [19]. Further research is needed
to evaluate the safety of antiplatelet agent in patients with diabet-
ic kidney disease.
Our study had the following strengths:
Firstly, we looked at a relatively large population of patients with
diabetic nephropathy in a multi-ethnic Asian population with a
follow up period of up to 6 years.
Secondly, the death data were obtained from the Death Regis-
try where it is required by law for all deaths occurring in Singapore
to be registered within 24 hours of occurrence.
Our study has its limitations. Firstly, there is now a new classi-
ﬁcation for CKD proposed by Kidney Disease: Improving Global
Outcomes (DDGIO) [14]. However, this study was unable to use the
latest classiﬁcation as the cause of CKD was not captured and 17.1%
of the patients did not do urine test for albumin at baseline. Sec-
ondly, we have only looked at baseline use of ACEi and/or ARBs and
patients may have switched or stopped drugs over the years. A
similar study showed that discontinuation rates of ACEI/ARB were
high: only 66% of treated patients received renewed prescriptions
on >50% of their follow-up visits, and only <10% of patients re-
mained on ACEI/ARB therapy throughout all follow-up visits.9 This
may affect the effect of these drugs on the mortality of CKD, there-
fore causing the effect to be non-signiﬁcant after adjustments.
Thirdly, the retrospective cohort study design would not allow us
to explore variables that were not collected at the start of the study.
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Figure 1. Kaplan–Meier survival estimate.
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Being an observational study, we could only assess association but
not causation. Furthermore, renal biopsy results were not avail-
able and as such patients may have other coexisting renal diseases.
Lastly. we have used backwards elimination of non-signiﬁcant
variables which is prone to overﬁtting the data. However, the aim
of the study was not to derive a predictive model for predicting
mortality and thus we did not test the variables on a validation
cohort.
Conclusion
We have estimated the annual mortality rate for patients with
diabetic kidney disease by CKD stages and identiﬁed predictors of
mortality. This study has aﬃrmed the poor prognosis of these pa-
tients and an urgency to act to prevent the progression to later stages
of CKD. We can also leverage on the use of information technolo-
gy by incorporating the regression equation to determine the
mortality rate for individual patient depending on his/her risk factors
and look at how we can improve the modiﬁable ones.
References
[1] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis
2002;39(2 Suppl. 1):S1–266. [Epub 2002/03/21]. PubMed PMID: 11904577.
[2] Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in
population-based studies: systematic review. BMC Public Health 2008;8:117.
[Epub 2008/04/15]. PubMed PMID: 18405348. Pubmed Central PMCID:
PMC2377260.
[3] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al.
Global and regional mortality from 235 causes of death for 20 age groups in
1990 and 2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet 2012;380(9859):2095–128. [Epub 2012/12/19]. PubMed PMID:
23245604.
[4] Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to
action. Am J Med Sci 2006;331(3):150–3. [Epub 2006/03/16]. PubMed PMID:
16538076.
[5] Lim CC, Teo BW, Ong PG, Cheung CY, Lim SC, Chow KY, et al. Chronic kidney
disease, cardiovascular disease and mortality: a prospective cohort study in a
multi-ethnic Asian population. Eur J Prev Cardiol 2014;22(8):1018–26. [Epub
2014/05/27]. PubMed PMID: 24857889.
[6] Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE,
et al. Association of estimated glomerular ﬁltration rate and albuminuria with
all-cause and cardiovascular mortality in general population cohorts: a
collaborative meta-analysis. Lancet 2010;375(9731):2073–81. [Epub 2010/05/
21]. PubMed PMID: 20483451. Pubmed Central PMCID: PMC3993088.
[7] Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney
disease and mortality risk: a systematic review. J Am Soc Nephrol
2006;17(7):2034–47. [Epub 2006/06/02]. PubMed PMID: 16738019.
[8] Woo KT, Choong HL, Wong KS, Tan HB, Chan CM. The contribution of
chronic kidney disease to the global burden of major noncommunicable
diseases. Kidney Int 2012;81(10):1044–5. [Epub 2012/05/01]. PubMed PMID:
22543907.
[9] Loh PT, TohMP, Molina JA, Vathsala A. Ethnic disparity in prevalence of diabetic
kidney disease in an Asian primary healthcare cluster. Nephrology (Carlton)
2015;20(3):216–23. [Epub 2014/12/17]. PubMed PMID: 25495003.
[10] NHG Corporate Yearbook 2014/2015. Singapore: National Healthcare Group;
Group Corporate Communications, National Healthcare Group; 88 p.
[11] Heng BH, Sun Y, Cheah JT, Jong M. The Singapore National Healthcare Group
Diabetes Registry – descriptive epidemiology of type 2 diabetes mellitus. Ann
Acad Med Singapore 2010;39(5):348–52. [Epub 2010/06/11]. PubMed PMID:
20535422.
[12] Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al.
Kidney disease as a risk factor for development of cardiovascular disease: a
statement from the American Heart Association Councils on Kidney in
Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and
Epidemiology and Prevention. Circulation 2003;108(17):2154–69. [Epub
2003/10/29]. PubMed PMID: 14581387.
[13] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and
the risks of death, cardiovascular events, and hospitalization. NEJM
2004;351(13):1296–305. PubMed PMID: 15385656.
[14] Group KDIGOKBPW. KDIGO 2012 clinical practice guideline for the evaluation
and management of chronic kidney disease. Kidney Int 2013;1–163.
[15] George PP, Oh CM, Loh PT, Heng BH, Lim FS. Right-siting chronic kidney disease
care-a survey of general practitioners in Singapore. Ann Acad Med Singapore
2013;42(12):646–56. [Epub 2014/01/28]. PubMed PMID: 24463826.
[16] Sng QS. Primary Care Survey 2010 Proﬁle of Primary Care Patients. Singapore:
Ministry of Health, Singapore; 2011.
Table 3
Univariate hazard ratios and 95% conﬁdence intervals for mortality
Covariates Hazard ratio (95%
conﬁdence interval)
P value
Age 1.06 (1.05–1.06) <0.001
Diabetes onset age 1.04 (1.03–1.04) <0.001
Gender
Female Reference
Male 1.15 (1.01–1.30) 0.030
Race
Chinese Reference
Malay 0.80 (0.67–0.96) 0.013
Indian 1.07 (0.84–1.36) 0.582
Others 1.00 (0.72–1.38) 0.987
Duration of diabetes 0.998 (0.989–1.01) 0.681
HBA1c 0.978 (0.937–1.02) 0.316
Creatinine 1.003 (1.002–1.003) <0.001
Glomerular ﬁltration rate 0.96 (0.96–0.97) <0.001
CKD stage
3A Reference
3B 1.56 (1.31–1.85) <0.001
4 2.68 (2.24–3.20) <0.001
5 5.48 (4.45–6.75) <0.001
Albuminuria
None Reference
Microalbuminuria 1.47 (1.12–1.92) 0.006
Macroalbuminuria 2.60 (2.00–3.38) <0.001
Unknown 3.39 (2.58–4.47) <0.001
Comorbid conditions
Hypertension 1.05 (0.76–1.46) 0.758
Dyslipidaemia 0.96 (0.64–1.44) 0.846
Ischaemic heart disease 1.56 (1.36–1.79) <0.001
Cerebrovascular disease 1.52 (1.28–1.81) <0.001
Retinopathy 1.37 (1.15–1.64) 0.001
Peripheral vascular disease 2.04 (1.65–2.53) <0.001
Neuropathy 1.94 (1.51–2.50) <0.001
ACEi/ARB
None Reference
ACEi 0.59 (0.50–0.69) <0.001
ARB 0.60 (0.49–0.73) <0.001
Both 0.68 (0.54–0.85) 0.001
Diabetes treatment
Diet Reference
Oral hypoglycaemic agents only 0.82 (0.69–0.98) 0.031
Insulin only 1.51 (1.18–1.93) 0.001
Both oral hypoglycaemic agents and insulin 0.84 (0.68–1.05) 0.120
Statins 0.84 (0.72–0.98) 0.027
Antiplatelet agent 1.69 (1.49–1.92) <0.001
Table 4
Multivariate hazard ratios and 95% conﬁdence intervals for mortality
Covariates Hazard ratio (95%
conﬁdence interval)
P value
Age 1.06 (1.05–1.06) <0.001
Gender
Female Reference
Male 1.38 (1.21–1.57) <0.001
CKD stage
3A Reference
3B 1.37 (1.15–1.62) <0.001
4 2.02 (1.69–2.43) <0.001
5 4.24 (3.41–5.29) <0.001
Albuminuria
None Reference
Microalbuminuria 1.45 (1.10–1.90) 0.008
Macroalbuminuria 2.17 (1.66–2.84) <0.001
Unknown 2.35 (1.77–3.11) <0.001
Comorbid conditions
Peripheral vascular disease 2.04 (1.65–2.53) 0.021
Neuropathy 1.49 (1.14–1.94) 0.004
Retinopathy 1.32 (1.09–1.60) 0.004
Antiplatelet agent 1.36 (1.19–1.55) <0.001
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